Also known as: lecanemab-irmb, Lecanemab-irmb, Leqembi, Leqembi Iqlik
Lecanemab-irmb is an amyloid beta-directed monoclonal antibody marketed as Leqembi for Alzheimer's disease. It is used in early-stage disease settings such as mild cognitive impairment or mild dementia due to Alzheimer's pathology. The FDA first approved Leqembi on January 6, 2023.
FDA approved a subcutaneous starting dose of Leqembi for early Alzheimer's disease. AAIC 2026 real-world data showed most patients stable or improved; a mouse study found KCL-286 repaired DNA damage and reduced inflammation.
A preclinical study shows that the anti-epileptic drug levetiracetam can prevent the formation of amyloid-beta 42 in neurons by modulating synaptic vesicle recycling. Analysis of patient records indicates a modest delay in cognitive decline among Alzheimer's patients taking the drug, suggesting potential for very early preventive use.
Biogen's Phase 2 CELIA trial showed diranersen slowed Alzheimer's decline and cut tau biomarkers, but missed the dose-response goal. Leqembi sales data is expected next quarter.
Two recent studies advance Alzheimer's research: one finds combining anti-amyloid antibodies with natural compounds improves efficacy and safety, while another maps a molecular cascade that could reveal new therapeutic targets. The combination therapy study used aducanumab, lecanemab, resveratrol, and curcumin. The molecular study identified gene expression networks and proposed a two-stage disease model.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
Alzheimer's blood tests are gaining FDA clearances and strong patient interest, yet surveys show clinicians remain skeptical about their reliability and clinical benefit. A UK survey found fewer than one-third of psychiatrists have used biomarkers, while only 6% of memory services meet access guidelines. An ethical framework urges careful implementation, especially in primary care.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.
A new Cochrane review said anti-amyloid Alzheimer’s drugs show no clinically meaningful benefit, but many researchers said the analysis has major limitations. Newer evidence on lecanemab and donanemab and broader drug development efforts continue to shape the field.
A review of 17 studies involving 20,342 patients found anti-amyloid Alzheimer’s drugs had “trivial” effects after 18 months and increased the risk of brain swelling and bleeding. A separate PET study suggested ARIA-E may mark brain regions with greater amyloid plaque reduction.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07688460 |
Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's Biomarkers |
RECRUITING | PHASE4 |
| NCT07544953 |
Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology |
NOT_YET_RECRUITING | NA |
| NCT06602258 |
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06530732 |
Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study) |
RECRUITING | PHASE3 |
| NCT06384573 |
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06285448 |
Feasibility of Lecanemab Registry and Clinical Outcome Measures |
ENROLLING_BY_INVITATION | |
| NCT05925621 |
Cognitive Neurology Unit Clinical Registry |
RECRUITING | |
| NCT05533801 |
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants |
COMPLETED | PHASE1 |
| NCT05469009 |
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy |
ACTIVE_NOT_RECRUITING | EARLY_PHASE1 |
| NCT05269394 |
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) |
ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
